These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 17485906)

  • 21. Changes in endocrine therapy: anastrozole and advanced breast cancer in postmenopausal women.
    Nabholtz JM
    Am J Hosp Palliat Care; 2004; 21(6):457-65. PubMed ID: 15612238
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of goserelin in the treatment of breast cancer.
    Rody A; Loibl S; von Minckwitz G; Kaufmann M
    Expert Rev Anticancer Ther; 2005 Aug; 5(4):591-604. PubMed ID: 16111461
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Extended therapy with letrozole and ovarian suppression in premenopausal patients with breast cancer after tamoxifen.
    Ruddy KJ; DeSantis SD; Barry W; Guo H; Block CC; Borges V; Winer EP; Partridge AH
    Clin Breast Cancer; 2014 Dec; 14(6):413-6. PubMed ID: 24970714
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjuvant endocrine therapy for breast cancer.
    Rao RD; Cobleigh MA
    Oncology (Williston Park); 2012 Jun; 26(6):541-7, 550, 552 passim. PubMed ID: 22870539
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Luteinizing hormone-releasing hormone analogues--the rationale for adjuvant use in premenopausal women with early breast cancer.
    Jonat W
    Br J Cancer; 1998 Sep; 78 Suppl 4(Suppl 4):5-8. PubMed ID: 9741781
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Update on endocrine therapy for breast cancer.
    Buzdar AU; Hortobagyi G
    Clin Cancer Res; 1998 Mar; 4(3):527-34. PubMed ID: 9533518
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The use of GnRH analogues in early and advanced breast carcinomas].
    Ségura C; Avenin D; Gligorov J; Selle F; Estéso A; Beerblock K; Emile G; Do Huyen N; Lotz JP
    Gynecol Obstet Fertil; 2005 Nov; 33(11):914-9. PubMed ID: 16246613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
    Carpenter R
    Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer.
    Perez EA
    Ann Oncol; 2007 Sep; 18 Suppl 8():viii26-35. PubMed ID: 17890211
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal women.
    Cardoso F; Bischoff J; Brain E; Zotano ÁG; Lück HJ; Tjan-Heijnen VC; Tanner M; Aapro M
    Cancer Treat Rev; 2013 Aug; 39(5):457-65. PubMed ID: 22840697
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer.
    Forward DP; Cheung KL; Jackson L; Robertson JF
    Br J Cancer; 2004 Feb; 90(3):590-4. PubMed ID: 14760369
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimal adjuvant endocrine therapy for early breast cancer.
    Stuart-Harris R; Davis A
    Womens Health (Lond); 2010 May; 6(3):383-98. PubMed ID: 20426605
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer.
    Sverrisdottir A; Johansson H; Johansson U; Bergh J; Rotstein S; Rutqvist L; Fornander T
    Breast Cancer Res Treat; 2011 Aug; 128(3):755-63. PubMed ID: 21625929
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current status of endocrine therapy for breast cancer.
    Miyoshi Y; Taguchi T; Tamaki Y; Noguchi S
    Breast Cancer; 2003; 10(2):105-11. PubMed ID: 12736562
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predicting benefit of endocrine therapy for early breast cancer.
    Regan MM
    Breast; 2015 Nov; 24 Suppl 2(0 2):S129-31. PubMed ID: 26255197
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The evolution of adjuvant endocrine therapy: developments since St Gallen 2005.
    Smith IE; Arnedos M
    Breast; 2007 Dec; 16 Suppl 2():S4-9. PubMed ID: 17764939
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.
    Mouridsen HT; Robert NJ
    Eur J Cancer; 2005 Aug; 41(12):1678-89. PubMed ID: 16098456
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women.
    Robertson JF; Blamey RW
    Eur J Cancer; 2003 May; 39(7):861-9. PubMed ID: 12706354
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.
    Dunn C; Keam SJ
    Pharmacoeconomics; 2006; 24(5):495-517. PubMed ID: 16706574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.